Ardelyx
Clinical trials sponsored by Ardelyx, explained in plain language.
Biopharmaceutical company developing treatments for gastrointestinal and kidney diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug could ease teen IBS constipation pain Results expected Sep 2026 (estimated) 🚀 Make-or-break
- New drug aims to ease chronic constipation in large trial Results expected Feb 2027 (estimated) 🚀 Make-or-break
-
New drug tested for kids with chronic constipation
Symptom relief By invitation onlyThis study is testing the long-term safety of tenapanor (Ibsrela) in children aged 6 to 17 with irritable bowel syndrome with constipation (IBS-C). About 150 kids who completed a prior study will continue taking the drug for up to one year. Researchers will monitor side effects a…
Phase 3 • Sponsor: Ardelyx • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
New drug could ease teen IBS constipation pain
Symptom relief OngoingThis phase 3 trial tests tenapanor, a drug that helps with constipation and belly pain, in 180 teenagers aged 12 to 17 with irritable bowel syndrome and constipation (IBS-C). Participants take either a low or high dose of tenapanor or a placebo twice daily for 12 weeks. The goal …
Phase 3 • Sponsor: Ardelyx • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC